Emerging technologies in extracellular vesicle-based molecular diagnostics Shidong Jia, Davide Zocco, Michael L Samuels, Michael F Chou, Roger Chammas, Johan Skog, Natasa Zarovni, Fatemeh, Momen-Heravi, and Winston Patrick Kuo
Today, GE Reports Blog published a post featuring our latest financing round from GE Ventures. Here are a few excerpts from the post: RainDance Technologies is developing new “liquid biopsy” systems using tiny droplets separated by oil to analyze DNA. Researchers using the technology
GE Ventures support RainDance’s vision to make liquid biopsy a commercial reality BILLERICA, Mass. – March 3, 2014 – RainDance Technologies, Inc., an innovative genomics tools company making molecular testing of complex diseases more standardized and readily available, today announced
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.